• PDB50 MEDICATION BELIEFS AMONG LOW-INCOME AFRICAN AMERICANS AND CAUCASIANS WITH DIABETES

    May 1, 2011, 00:00

  • PND54 RETROSPECTIVE DATABASE ANALYSIS OF FREQUENCY AND COSTS OF RELAPSES AMONG MULTIPLE SCLEROSIS PATIENTS

    May 1, 2011, 00:00

  • PMH65 EFFECT OF PRESCRIPTION MONITORING PROGRAMS (PMP'S) ON OPIOID OVERDOSE ADMISSION

    May 1, 2011, 00:00

  • PIN37 HOW MANY IMMUNIZATION DOSES WERE MISSED IN PEDIATRICES YOUNGER THAN 2 YEARS?

    May 1, 2011, 00:00

  • PRM25 PSYCHOMETRIC COMPARIBILITY OF SINGLE ITEM AND GRID FORM ADMINISTRATION OF THE SF-36V2™ HEALTH SURVEY

    May 1, 2011, 00:00

  • PRS40 TRENDS IN ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS FOR ADULTS IN THE UNITED STATES WITH NASOPHARYNGITIS, UPPER RESPIRATORY TRACT INFECTIONS AND BRONCHITIS FROM 2006 TO 2008

    May 1, 2011, 00:00

  • PSY41 HEALTH-RELATED QUALITY OF LIFE IN KAZAKHSTAN PATIENTS WITH HEREDITARY COAGULOPATHIES

    May 1, 2011, 00:00

  • ISPOR 16TH Annual International Meeting Research Abstracts Author Index

    May 1, 2011, 00:00

  • PHP6 EXPLORE THE USE OF DRUGS IN MEDICAL INSURANCE BILLING IN CHINA

    May 1, 2011, 00:00

  • PCV82 EVALUATION OF RELATIONSHIP BETWEEN BLOOD PRESSURE CONTROL AMONG HYPERTENSIVE PATIENTS AND INTEGRATION OF SERVICES WITHIN PHYSICIAN ORGANIZATIONS

    May 1, 2011, 00:00

  • PCN99 ITALIAN MONITORING REGISTRY OF BEVACIZUMAB IN THE TREATMENT OF METASTATIC COLON RECTAL CARCINOMA

    May 1, 2011, 00:00

  • CE2 A NOVEL WAY OF ESTIMATING COST-EFFECTIVENESS RATIOS FROM CLINICAL TRIALS WITH MISSING DATA- A SIMULATION STUDY

    May 1, 2011, 00:00

  • PCN89 HTA AGENCIES' PREFERENCES REGARDING QUALITY OF LIFE MEASURES FOR PROSTATE CANCER CLINICAL TRIALS

    May 1, 2011, 00:00

  • PRS44 THE CHARIOT STUDY- NOVEL DATA COLLECTION, VIEWING AND DYNAMIC REPORTING MECHANISM

    May 1, 2011, 00:00

  • PSY61 CHARACTERISTICS OF GOLIMUMAB UTILIZATION AND COSTS IN A SPECIALTY PHARMACY PROVIDER (SPP) SETTING

    May 1, 2011, 00:00

  • PIH4 COMPARATIVE EFFECTIVENESS OF BANKED DONOR MILK FOR PREMATURE INFANTS- EFFICIENCY OF A MILK BANK MODEL INTEGRATED IN A BLOOD BANK SETTING

    May 1, 2011, 00:00

  • PGI20 IBS-C PATIENT SYMPTOM REPORTS- ANALYSIS OF EXPLORATORY OPEN-ENDED QUESTIONS

    May 1, 2011, 00:00

  • PHP46 THE STATE OF HEALTH ECONOMIC EVALUATION IN SOUTH AFRICA- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PUK7 ECONOMIC EVALUATION OF CINACALCET VERSUS STANDARD TREATMENT IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM IN MEXICO

    May 1, 2011, 00:00

  • PHP11 REVIEW OF ADJUSTMENT OF ESSENTIAL MEDICINE LIST AT PROVINCIAL LEVEL IN CHINA

    May 1, 2011, 00:00

  • PRS4 LITERATURE REVIEW OF RISK FACTORS FOR MORTALITY OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2011, 00:00

  • PMD4 PERCEPTION OF IRON DEFICIENCY IN CLINICAL PRACTICES- MULTIDISCIPLINARY FRENCH SURVEY (SUPFER SURVEY)

    May 1, 2011, 00:00

  • PDB7 DIET THERAPIES IN PATIENTS WITH TYPE-2 DIABETES- A MIXED-TREATMENT COMPARISON OF RANDOMIZED CONTROL TRIALS

    May 1, 2011, 00:00

  • PMS30 COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS STANDARD CARE IN THE TREATMENT OF POST-MENOPAUSAL OSTEOPOROSIS IN PORTUGAL

    May 1, 2011, 00:00

  • PSY11 BURDEN OF ILLNESS IN FIBROMYALGIA SYNDROME- THE PATIENTS' PERSPECTIVES

    May 1, 2011, 00:00

  • PMS2 ATRIAL FIBRILLATION IN OSTEOPOROTIC WOMEN TREATED WITH ALENDRONATE

    May 1, 2011, 00:00

  • PHP61 WIDER CONSULTATION IN HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS- BETTER UNDERSTANDING OR A LOBBYING OPPORTUNITY?

    May 1, 2011, 00:00

  • PCN42 COSTS OF HOSPITAL EVENTS IN PATIENTS WITH METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PIN4 EFFICACY AND SAFETY OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAïVE ADULT PATIENTS WITH HIV-1 INFECTION- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PMH10 THE INFLUENCE OF COMORBID ANXIETY ON MEDICATION USE AND SERVICE UTILIZATION AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER- RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE

    May 1, 2011, 00:00

  • PDB71 CHARACTERISTICS OF EARLY ADOPTERS OF EXPENSIVE MEDICATIONS

    May 1, 2011, 00:00

  • PCN100 RACIAL DISPARITIES IN AFRICAN AMERICAN VERSUS WHITE WOMEN WITH NEWLY DIAGNOSED BREAST CANCER IN A SOUTHEAST UNITED STATES HEALTH PLAN

    May 1, 2011, 00:00

  • PDB43 TREATMENT COMPLIANCE TO DIABETES CARE- A CROSS-SECTIONAL STUDY FROM PAKISTAN

    May 1, 2011, 00:00

  • PIH16 COST-EFFECTIVENESS OF DESVENLAFAXINE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS IN BREAST CANCER PATIENTS IN MEXICO

    May 1, 2011, 00:00

  • PCV11 PNEUMONIA AFTER ACUTE ISCHEMIC STROKE- PREVALENCE, ASSOCIATED FACTORS AND OUTCOMES

    May 1, 2011, 00:00

  • PUK19 KIT73- PRELIMINARY REPORTS OF IMMUNOSUPRESSANT THERAPY PATTERNS IN A COHORT OF POST KIDNEY TRANSPLANT PATIENTS IN BRAZIL

    May 1, 2011, 00:00

  • PDB12 USE OF ANTIDEPRESSANTS AND THE RISK OF DIABETES MELLITUS- A NESTED CASE-CONTROL STUDY

    May 1, 2011, 00:00

  • PCN116 TRANSFERABILITY OF NICE RECOMMENDATIONS FOR PHARMACEUTICAL THERAPIES IN ONCOLOGY TO CENTRAL-EASTERN EUROPEAN COUNTRIES

    May 1, 2011, 00:00

  • PUK5 TREATMENT PATTERNS IN OVERACTIVE BLADDER- REAL-WORLD PATIENT POPULATION

    May 1, 2011, 00:00

  • PSU10 COST-EFFECTIVENESS OF PRIMARY PCI WITHOUT ONSITE SURGICAL BACKUP

    May 1, 2011, 00:00

  • PCN73 UTILISATION OF ANTINEOPLASTIC AGENTS IN SLOVAK REPUBLIC

    May 1, 2011, 00:00

  • PSY13 THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES- ANALYSIS FROM A COMMERCIAL CLAIMS DATABASE

    May 1, 2011, 00:00

  • SB1 COMPARISON OF DIFFERENCE-IN-DIFFERENCE, PROPENSITY SCORE MATCHING AND INSTRUMENTAL VARIABLES IN ESTIMATING COST DIFFERENCES BETWEEN TWO COHORTS

    May 1, 2011, 00:00

  • PIN21 COST EFFECTIVENESS ANALYSIS OF VACCINATION PROGRAMS WITH 10-VALENT (PCV10) AND 13-VALENT (PCV13) PNEUMOCOCCAL VACCINES IN COLOMBIA

    May 1, 2011, 00:00

  • PCV62 PERSISTENCE AND COMPLIANCE IN HYPERTENSION TREATMENT WITH OLMESARTAN MEDOXOMIL – ANALYSIS OF REAL-LIFE PRESCRIPTION DATA

    May 1, 2011, 00:00

  • PHP44 DURATION OF PATIENTS VISITS TO THE EMERGENCY DEPARTMENT

    May 1, 2011, 00:00

  • PHP88 INFLUENCE OF HOSPITAL CHOICES OF DRUGS ON THE PHARMACEUTICAL CONSUMPTION IN THE COMMUNITY

    May 1, 2011, 00:00

  • PCN71 USING MEASURES OF SOCIETAL VALUE AND ECONOMIC MODELING TO ESTIMATE PRICES FOR CANCER DRUGS IN SOUTH AFRICA

    May 1, 2011, 00:00

  • PRM24 EXPLORING THE INTERRELATIONSHIP BETWEEN UNINTENTIONAL AND INTENTIONAL NONADHERENCE AMONG 24,071 ADULTS WITH CHRONIC DISEASE

    May 1, 2011, 00:00

  • PMS21 ABATACEPT OR INFLIXIMAB FOR RHEUMATOID ARTHRITIS IN VENEZUELA? A COST-EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • PMH49 CAN THE ILLNESS PERCEPTION QUESTIONNAIRE BE USED TO ASSESS MENTAL HEALTH PRACTITIONERS' PERSPECTIVES ON PATIENTS WITH SCHIZOPHRENIA?

    May 1, 2011, 00:00

  • PSU13 MORBID OBESITY AND HEALTH RELATED QUALITY OF LIFE

    May 1, 2011, 00:00

  • PCV42 A DECISION MODELING APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION

    May 1, 2011, 00:00

  • PSY32 HOW DO MINIMALLY IMPORTANT DIFFERENCES VALUE OUTCOMES?

    May 1, 2011, 00:00

  • PSY60 ECONOMIC CONSEQUENCES OF UNDER-UTILIZATION WITH TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2011, 00:00

  • PSY45 CHARACTERISTICS OF CAREGIVERS AND THEIR EXPERIENCE ASSOCIATED WITH CONGENITAL HEMOPHILIA OF INHIBITOR PATIENTS

    May 1, 2011, 00:00

  • PSY43 HEALTH-RELATED QUALITY OF LIFE IN UKRAINE PATIENTS WITH HEREDITARY COAGULOPATHIES

    May 1, 2011, 00:00

  • PHP65 HEALTH OUTCOMES AND ECONOMICS RESEARCH FOR CELLULAR THERAPIES AND REGENERATIVE MEDICINES- LESSONS FROM A HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT ANALYSIS IN THE UNITED STATES

    May 1, 2011, 00:00

  • MD1 USING COST-EFFECTIVENESS INFORMATION TO ALLOCATE MEDICARE RESOURCES – HOW MUCH MORE HEALTH FOR THE MONEY?

    May 1, 2011, 00:00

  • PMD12 GENDER DIFFERENCES IN TOTAL KNEE ARTHROPLASTY (TKA) POSTOPERATIVE PAIN MANAGEMENT IN THE UNITED STATES

    May 1, 2011, 00:00

  • PIH35 PHARMACISTS' ATTITUDE AND PREPAREDNESS REGARDING THE ISSUE OF ESCALATING PHARMACEUTICAL DEMAND DUE TO THE AGING BABY BOOMERS

    May 1, 2011, 00:00

  • DU4 THE LONG TERM UTILIZATION OF STIMULANTS IN CHILDREN AND ADOLESCENTS- A MEDICAID STUDY

    May 1, 2011, 00:00

  • PCN17 MULTI-COHORT MODEL OF PREVALENCE ESTIMATION OF ADVANCED MALIGNANT MELANOMA IN THE UNITED STATES- RESULTS COMPARED TO SEER DATA

    May 1, 2011, 00:00

  • PMH45 MEASURES OF MEDICATION ADHERENCE IN ORAL VERSUS LONG-ACTING RISPERIDONE IN TEXAS MEDICAID PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PND6 THE IMPACT OF SPECIALTY CARE PROGRAMS ON RELAPSES OF MULTIPLE SCLEROSIS USING ADMINISTRATIVE DATA

    May 1, 2011, 00:00

  • PMH37 THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS

    May 1, 2011, 00:00

  • PCN2 SAFETY AND TREATMENT PATTERNS OF ANGIOGENESIS INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE UNITED KINGDOM- PRELIMINARY RESULTS OF AN ONGOING CHARTS REVIEW STUDY

    May 1, 2011, 00:00

  • PSS2 DIAGNOSED AND UNDIAGNOSED DRY EYE, SYMPTOM SEVERITY, AND ASSOCIATED FACTORS AMONG MEN AND WOMEN IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMD8 POSITRON EMISSION TOMOGRAPHY SCREENING FOR LUNG CANCER- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PND2 AN EPIDEMOLOGIC EVALUATION OF COMORBID CONDITIONS IN PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PCV78 HEALTH RELATED QUALITY OF LIFE IN HYPERTENSIVE PATIENTS VISITING PUBLIC HOSPITALS OF QUETTA, PAKISTAN

    May 1, 2011, 00:00

  • PIN7 EPIDEMIOLOGY OF HIV-RELATED NEUROPATHY – A SYSTEMATIC LITERATURE REVIEW

    May 1, 2011, 00:00

  • PDB26 ECONOMIC EVALUATION OF GLIMEPIRIDE AND GLIMEPIRIDE/METFORMIN FOR TYPE-2 DIABETES MELLITUS IN MEXICO

    May 1, 2011, 00:00

  • PIH32 THE ASSOCIATION OF MENOPAUSAL SYMPTOMS, INCLUDING HOT FLASHES, WITH QUALITY OF LIFE, WORK PRODUCTIVITY AND RESOURCE USE

    May 1, 2011, 00:00

  • PMD30 IMPACT OF ACCESS TO A USUAL SOURCE OF CARE ON COMPLIANCE TO BREAST AND CERVICAL CANCER SCREENING

    May 1, 2011, 00:00

  • PHP48 STATUS OF PHARMACIST AT COMMUNITY LEVEL- AN EXPLORATORY STUDY IN QUETTA, PAKISTAN

    May 1, 2011, 00:00

  • PND7 PREVALENCE OF DRUG-TREATED MULTIPLE SCLEROSIS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM- COMPARATIVE ANALYSIS WITH PUBLISHED PREVALENCE RATES

    May 1, 2011, 00:00

  • PRS14 A COST-EFFECTIVENESS ANALYSIS ON THE USE OF INDACATEROL FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN MEXICO

    May 1, 2011, 00:00

  • PMH38 ECONOMIC IMPLICATIONS OF THE EFFECT OF LURASIDONE VERSUS OTHER SELECTED ATYPICAL ANTIPSYCHOTICS ON CARDIOMETABOLIC PARAMETERS IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PND15 THE INCREMENTAL COST OF ALZHEIMER'S DISEASE IN THE CALIFORNIA MEDICAID PROGRAM (MEDI-CAL)

    May 1, 2011, 00:00

  • PMD23 COST-EFFECTIVENESS OF SPECIFIC USE OF THE LANCET BD QUIKHEEL® IN SCREENING PROGRAM OF NEONATAL CONGENITAL HYPOTHYROIDISM IN MEXICO

    May 1, 2011, 00:00

  • PHP29 EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH INSURANCE- THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA

    May 1, 2011, 00:00

  • PCN35 DOSING PATTERN AND COST COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA INPATIENTS

    May 1, 2011, 00:00

  • PND64 APPLICATION OF PREDICTIVE MODELING TO CLASSIFY FREQUENT SNORING IDENTIFIED FROM ROUTINE MEDICAL EXAMINATIONS USING THE NHANES DATABASE

    May 1, 2011, 00:00

  • EE3 PERFORMANCE OF DIFFERENT COMORBIDITY MEASURES IN PREDICTING HEALTH CARE EXPENDITURE IN PATIENTS WITH DEMENTIA

    May 1, 2011, 00:00

  • PMH19 THE BUDGET IMPACT ANALYSIS OF NALTREXONE IN THE TREATMENT OF ALCOHOL-DEPENDENT PATIENTS IN POLAND

    May 1, 2011, 00:00

  • PND18 BURDEN OF WALKING AND MOBILITY PROBLEMS IN MS- ANALYSIS OF CAREGIVER AND INDIRECT COSTS

    May 1, 2011, 00:00

  • PCV112 EXTENSION OF META-ANALYSIS IN COMPARING OF FIMASARTAN WITH LOSARTAN IN BLOOD PRESSURE LOWERING EFFECT

    May 1, 2011, 00:00

  • PIH31 SELF MEDICATION- ASSESSMENT OF STATUS, PRACTICES AND PERCEPTION

    May 1, 2011, 00:00

  • PMH47 THE RELATIONSHIP BETWEEN BUPRENORPHINE-MEDICATION ASSISTED TREATMENT ADHERENCE AND HEALTH CARE COSTS AND SERVICE UTILIZATION- AN ANALYSIS OF AETNA'S OPIOID DEPENDENT MEMBERS

    May 1, 2011, 00:00

  • PCN92 PSYCHOMETRIC COMPARISION OF THE EQ-5D-3L TO THE EQ-5D-5L IN CANCER PATIENTS IN KOREA

    May 1, 2011, 00:00

  • PDB13 USE OF ANTIDEPRESSANTS AND THE RISK OF DIABETES MELLITUS- A RETROSPECTIVE COHORT STUDY

    May 1, 2011, 00:00

  • PMD10 SCREENING TREATMENT AND CONTROL OF HYPERTENSION IN DIABETIC PATIENTS USING OUTPATIENT VISIT DATA

    May 1, 2011, 00:00

  • PRS26 RELIABILITY AND VALIDITY OF THE EXACT-RESPIRATORY SYMPTOMS (E-RS) SCORE TO QUANTIFY THE SEVERITY OF RESPIRATORY SYMPTOMS OF COPD

    May 1, 2011, 00:00

  • PSS23 COMPARING HEALTH-RISK BURDEN AND TOTAL HEALTHCARE COSTS OF PSORIASIS WITH TOP FIVE CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • DU1 COMPARATIVE SAFETY OF STIMULANT AND ATOMOXETINE ASSOCIATED WITH THE RISK OF SUBSTANCE USE DISORDER AMONG ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PCV107 IDENTIFYING EFFICIENT ACUTE CLINICAL PATHWAYS FOR CHEST PAIN- USING RISK ADJUSTED COST-EFFECTIVENESS (RAC-E) TO COMPARE HOSPITALS USING LINKED, ROUTINELY COLLECTED DATA

    May 1, 2011, 00:00

  • PHP56 DEMONSTRATING CLINICAL-EFFECTIVENESS USING INDIRECT AND MIXED TREATMENT COMPARISON ANALYSIS- A REVIEW OF MANUFACTURERS' SINGLE TECHNOLOGY APPRAISAL (STA) SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

    May 1, 2011, 00:00

  • PHP89 THE IMPLEMENTATION OF PUBLIC HEALTH GUIDANCE- PREFERENCE FOR CLINICAL OVER BEHAVIOURAL INTERVENTIONS

    May 1, 2011, 00:00

  • PCN91 ARTHRALGIA AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER TAKING AROMATASE INHIBITORS- LONGITUDINAL ANALYSES

    May 1, 2011, 00:00

  • PCN117 ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ISS STAGE AND ECOG STATUS IN MULTIPLE MYELOMA

    May 1, 2011, 00:00

  • PRS33 EFFECTS OF EDUCATIONAL INTERVENTIONS FOR SELF-MANAGEMENT OF ASTHMA IN CHILDREN AND ADOLESCENTS- AN UPDATED SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

    May 1, 2011, 00:00

  • PHP43 THE INFLUENCE OF PATIENT ACCESS SCHEMES ON APPRAISAL DECISIONS BY NICE IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PMH3 RISK OF HIP FRACTURES IN ELDERLY MEDICARE BENEFICIARIES USING ATYPICAL OR TYPICAL ANTIPSYCHOTICS- A PROPENSITY SCORE ANALYSIS

    May 1, 2011, 00:00

  • PIN50 CARE ORGANIZATION AND AMBULATORY CARE SENSITIVE HOSPITALIZATIONS FOR BACTERIAL PNEUMONIA

    May 1, 2011, 00:00

  • PIN2 HEALTH OUTCOMES OF CLINICALLY RELEVANT PATIENT POPULATIONS TREATED WITH DAPTOMYCIN FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) SKIN INFECTIONS

    May 1, 2011, 00:00

  • PCV39 CHARACTERIZATION OF COSTS ASSOCIATED WITH STROKE REHABILITATION- A REVIEW OF THE LITERATURE

    May 1, 2011, 00:00

  • PND26 MEASURING THE IMPACT OF NATALIZUMAB THERAPY ON HEALTH CARE UTILIZATION IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

    May 1, 2011, 00:00

  • PSY64 GE CENTRICITY® ELECTRONIC MEDICAL RECORDS STUDY- COMORBIDITIES AND BIOLOGIC EXPERIENCE AMONG PATIENTS RECEIVING GOLIMUMAB

    May 1, 2011, 00:00

  • PMS14 DIRECT HEALTHCARE COSTS ASSOCIATED WITH OSTEOARTHRITIS

    May 1, 2011, 00:00

  • PSS21 GAP ANALYSIS FOR PATIENT-REPORTED OUTCOMES MEASURES FOR ALOPECIA

    May 1, 2011, 00:00

  • PHP74 CLINICAL TRIAL LEARNING CURVES AFFECT OUTCOMES MEASUREMENT, PATIENT SAFETY AND TRIAL SUCCESS- CONTRIBUTING FACTORS AND A POTENTIAL SOLUTION IN CLINICAL TRIAL SIMULATION

    May 1, 2011, 00:00

  • PCN20 EXERCISE LOWERS ESTROGEN AND PROGESTERONE LEVELS IN PREMENOPAUSAL WOMEN AT HIGH RISK OF BREAST CANCER

    May 1, 2011, 00:00

  • PHP17 PRESCRIPTION DRUG MONITORING PROGRAMS- THE PATIENT PERSPECTIVE

    May 1, 2011, 00:00

  • PCN57 ECONOMICS OF A MULTI-GENE ASSAY TO PREDICT RECURRENCE OF EARLY STAGE BREAST CANCER- EXPERIENCE OF A LARGE UNITED STATES INSURANCE PROGRAM

    May 1, 2011, 00:00

  • PRS19 COST-UTILITY OF VARENICLINE VERSUS INTERVENTIONS AVAILABLE FOR QUITTING SMOKING IN PANAMA USING THE BENESCO MODEL

    May 1, 2011, 00:00

  • PUK16 COST-EFFECTIVENESS OF VALGANCICLOVIR 200 DAYS PROPHYLAXIS VERSUS 100 DAYS PROPHYLAXIS IN KIDNEY TRANSPLANT PATIENTS AT HIGH-RISK FOR DEVELOPING CYTOMEGALOVIRUS DISEASE

    May 1, 2011, 00:00

  • PIN16 COST COMPARISON OF LINEZOLID VERSUS VANCOMYCIN FOR TREATMENT OF NOSOCOMIAL PNEUMONIA AND COMPLICATED SKIN AND SOFT TISSUE INFECTION CAUSED BY MRSA IN QUEBEC

    May 1, 2011, 00:00

  • PMH57 ASSOCIATION BETWEEN WORK PRODUCTIVITY AND SEVERITY OF DEPRESSION AMONG FULL-TIME EMPLOYEES AS MEASURED BY THE WPAI HPQ

    May 1, 2011, 00:00

  • PSU23 ASSESSING THE OUTCOME OF SHOULDER SURGERY- DEVELOPMENT, VALIDATION AND RESPONSIVENESS OF THE PATIENT-REPORTED OXFORD SHOULDER SCORE (OSS)

    May 1, 2011, 00:00

  • PMD24 GLYCOSYLATED HEMOGLOBIN OR FASTING GLUCOSE TESTING FOR SCREENING DIABETES IN COLOMBIA- A COST-EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • PDB70 BASELINE CHARACTERISTICS AND ANTIDIABETIC EXPOSURE IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH LIRAGLUTIDE

    May 1, 2011, 00:00

  • PHP113 IQWIG AND HIQA, WHAT ARE THEY GOOD FOR? THE EVOLUTION OF THE HTA AGENCY- TIME FROM CREATION TO FIRST ASSESSMENT AND IMPACTFUL APPRAISAL

    May 1, 2011, 00:00

  • PMH2 RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES

    May 1, 2011, 00:00

  • PIN11 EVALUATION OF COSTS AND INCOME OF AN EXTENDED TREATMENT OF CLINICAL MASTITIS CAUSED BY GRAM-POSITIVE PATHOGENS IN DAIRY COWS IN THE UNITED STATES- THE CASE OF PIRLIMYCIN

    May 1, 2011, 00:00

  • PMS29 COST-UTILITY ANALYSIS OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, LIMITED FASCIECTOMY, AND PERCUTANEOUS NEEDLE FASCIOTOMY IN DUPUYTREN'S CONTRACTURE

    May 1, 2011, 00:00

  • PCV24 EVALUATION OF THE CLINICAL FACTORS AND PREVENTIVE MEDICATIONS ASSOCIATED WITH THE LENGTH OF HOSPITAL STAY AMONG ISCHEMIC STROKE PATIENTS

    May 1, 2011, 00:00

  • PUK1 INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION

    May 1, 2011, 00:00

  • CO3 PROJECT LIBRA- A NEW ANALYTIC TOOL FOR COMPARATIVE EFFECTIVENESS ANALYSES OF MULTIPAYER CLAIMS DATABASES

    May 1, 2011, 00:00

  • PCV53 COST-EFFECTIVENESS ANALYSIS COMPARING IVABRADINE WITH ISOSORBIDE MONONITRATE, AMLODIPINE, DILTIAZEM AND VERAPAMIL, IN THE TREATMENT OF STABLE ANGINA PECTORIS

    May 1, 2011, 00:00

  • PMS8 THE BUDGET IMPACT OF LOWER GPA ADHERENCE IN PATIENTS WITH CHRONIC NON-STEROIDAL AND COX-2 INHIBITOR USE

    May 1, 2011, 00:00

  • PCV5 PREVALENCE, INCIDENCE, AND OUTCOMES OF CRITICAL LIMB ISCHEMIA IN THE MEDICARE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PDB36 AN ECONOMIC MODEL OF THE EFFECTS OF QUICK RELEASE BROMOCRIPTINE MESYLATE VERSUS ALTERNATIVE ORAL ANTIDIABETIC DRUGS ON HOSPITALIZATIONS AND COSTS

    May 1, 2011, 00:00

  • PCV77 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERTENSION IN KOREA

    May 1, 2011, 00:00

  • PMH31 TRAJECTORY ANALYSIS OF HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH HIGH DOSES OF DULOXETINE

    May 1, 2011, 00:00

  • PDB61 DECOMPOSING GENDER DIFFERENCES IN ANGIOTENSIN II CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS AMONG VETERANS WITH DIABETES

    May 1, 2011, 00:00

  • PSU16 LAPAROSCOPIC SUPRACERVICAL HYSTERECTOMY VERSUS LAPAROSCOPIC-ASSISTED VAGINAL HYSTERECTOMY- POST-SURGICAL OUTCOMES AND COSTS

    May 1, 2011, 00:00

  • PDB65 ECONOMIC BURDEN OF CUSHING'S DISEASE- A POPULATION ANALYSIS OF DIRECT MEDICAL COSTS AND UTILIZATION

    May 1, 2011, 00:00

  • PHP18 OPTIMAL HEALTH POLICY AND THE LINK BETWEEN OUTPUT MARKETS AND DEVELOPMENT

    May 1, 2011, 00:00

  • PND23 ECONOMIC EVALUATION OF DEXMEDETOMIDINE FOR SEDATION IN THE INTENSIVE CARE UNIT

    May 1, 2011, 00:00

  • PCN114 DEVELOPING A FAMILIAL CANCER RISK ASSESSMENT TOOL FOR USE IN UNDERSERVED COMMUNITIES

    May 1, 2011, 00:00

  • PUK20 EARLY DETECTION, SCREENING, AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AMONG ACTIVELY EMPLOYED – AN INTEGRATED POPULATION HEALTH MANAGEMENT APPROACH

    May 1, 2011, 00:00

  • PCV88 PATTERNS OF STATIN PRESCRIPTION AMONG PRIVATELY INSURED COMMERCIAL AND MEDICARE PATIENTS

    May 1, 2011, 00:00

  • PCN119 VALIDATION OF A NEW MEASURE OF PATIENT EMPOWERMENT IN ONCOLOGY- FIVE HEALTH EDUCATION IMPACT QUESTIONNAIRE (HEIQ) SCALES

    May 1, 2011, 00:00

  • PRM1 MEASURING COMORBIDITY- AN UPDATED CRITICAL REVIEW OF AVAILABLE METHODS

    May 1, 2011, 00:00

  • PHP49 UTILIZATION AND COST OF THE HEALTH PLAN - EFFECTS OF SPOUSAL BEREAVEMENT

    May 1, 2011, 00:00

  • PMS3 RISK FACTORS FOR NON-INITIATION OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARD) BY PATIENTS WITH NEWLY DIAGNOSED RHEUMATOID ARTHRITIS (RA)

    May 1, 2011, 00:00

  • PRM47 DEVELOPMENT OF LOCALLY ADAPTABLE VALUE ARGUMENTS- HOW CAN BUCKETING OF COUNTRIES AT GLOBAL LEVEL HELP MANUFACTURERS?

    May 1, 2011, 00:00

  • PCN41 FINANCIAL BURDEN AMONG PATIENTS WITH MAJOR CANCERS- FINDINGS FROM THE UNITED STATES MEDICAL EXPENDITURE PANEL SURVEY, 1996-2007

    May 1, 2011, 00:00

  • PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS

    May 1, 2011, 00:00

  • PSS30 BURDEN OF INFANTILE HEMANGIOMA- DEVELOPMENT OF A QUESTIONNAIRE

    May 1, 2011, 00:00

  • PND25 ECONOMIC TRENDS ASSOCIATED WITH NATALIZUMAB THERAPY IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION

    May 1, 2011, 00:00

  • PSY81 PERCEPTIONS ABOUT 'RAPID' WARFARIN REVERSAL WITH FRESH FROZEN PLASMA TO REDUCE THE INR- A NOVEL SURVEY METHODOLOGY

    May 1, 2011, 00:00

  • PCV72 THE RISK OF STROKE AND PREVENTATIVE STEPS AMONG PATIENTS DIAGNOSED WITH ATRIAL FIBRILLATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN4 BODY MASS INDEX AND STAGE OF DIAGNOSIS OF OVARIAN CANCER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2011, 00:00

  • PRS45 MODELING THE IMPACT OF MULTIPLE QUIT ATTEMPTS IN SMOKERS USING DISCRETE EVENT SIMULATION (DES)

    May 1, 2011, 00:00

  • PCN76 SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES LEAD TO CONSIDERABLE HEALTH RESOURCE UTILISATION IN EUROPE- ANALYSIS OF A MULTINATIONAL OBSERVATIONAL STUDY

    May 1, 2011, 00:00

  • PHP67 UNDERSTANDING THE VIETNAMESE PRICING AND REIMBURSEMENT ENVIRONMENT THROUGH A COMPARISON WITH THAT OF CHINA

    May 1, 2011, 00:00

  • PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO

    May 1, 2011, 00:00

  • CN3 THE VALUE OF RESEARCH FOR ERCC1 TESTING IN STAGE I NON-SMALL CELL LUNG CANCER

    May 1, 2011, 00:00

  • PDB66 COSTS OF THE PHARMACEUTICAL PROGRAM TO TREAT T2DM PATIENTS FROM HIPERDIA- GOVERNMENT HEALTH CARE PROGRAM FOR DIABETES AND HYPERTENSION POPULATION UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    May 1, 2011, 00:00

  • PGI7 THE ECONOMIC BURDEN OF REFRACTORY GERD- A RESTROSPECTIVE CLAIMS DATABASE STUDY

    May 1, 2011, 00:00

  • PRM27 SF-12 AND EQ-5D UTILITY SCORING STRATEGY- LESSONS FROM APPLYING 40 SCORINGS TO 3 LARGE DATA SETS

    May 1, 2011, 00:00

  • PHP76 THE OUTLOOK OF LARGE SIMPLE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH- AN APPLICATION OF THE PRECIS FRAMEWORK

    May 1, 2011, 00:00

  • PCV73 CONSTRUCT VALIDITY OF HEALTH UTILITIES INDEX (HUI) JAPANESE VERSION- CROSS-SECTIONAL STUDY FOR STROKE IN JAPAN

    May 1, 2011, 00:00

  • PIH44 MULTIDOMAIN LONGITUDINAL MODELING- APPLICATION TO THE INTERNATIONAL INDEX OF ERECTILE FUNCTION

    May 1, 2011, 00:00

  • PSY28 FACTORS LEADING TO HIGH HEALTH CARE EXPENDITURE AMONG OBESE INDIVIDUALS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PDB69 EXENATIDE (BID) AND LIRAGLUTIDE (QD) TREATMENT PATTERNS AMONG TYPE-2 DIABETES PATIENTS IN GERMANY

    May 1, 2011, 00:00

  • PDB25 COST OF ALL-CAUSE AND CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE BID, SULFONYLUREAS, OR INSULIN- A RETROSPECTIVE ANALYSIS OF THE LIFELINK DATABASE

    May 1, 2011, 00:00

  • PHP45 TRENDS OF HEALTH CARE UTILIZATION AMONG LOYAL PATIENTS IN A MEDICAL CENTER UNDER TAIWAN'S UNIVERSAL HEALTH INSURANCE PROGRAM

    May 1, 2011, 00:00

  • PIN6 TRENDS OF HEPATITIS A INCIDENCE FROM 2005 TO 2008

    May 1, 2011, 00:00

  • OR1 THE ASSOCIATION BETWEEN SELF-PERCEIVED COGNITIVE DIFFICULTIES AND LEVEL OF DEPRESSION AMONG EMPLOYEES WITH CURRENT DEPRESSION

    May 1, 2011, 00:00

  • PCN87 HOW DOES PATIENT-REPORTED OUTCOME DATA INFLUENCE THE CLINICAL DECISION MAKING OF PRACTICING ONCOLOGISTS?

    May 1, 2011, 00:00

  • PND65 TRANSLATABILITY ASSESSMENT OF THE POST-MIGRAINE QUESTIONNAIRE

    May 1, 2011, 00:00

  • PIH26 MEDICATION COMPLIANCE AND ITS AFFECTING FACTORS IN CLINICAL TRIALS IN SOUTH KOREA

    May 1, 2011, 00:00

  • PHP79 ROLE OF HTA SYSTEMS IN REIMBURSEMENT AND MARKET ACCESS- COMPARISON OF TURKEY AND POLAND

    May 1, 2011, 00:00

  • CO1 COMPARATIVE EFFECTIVENESS ANALYSIS OF TNF BLOCKERS IN RHEUMATOID ARTHRITIS (RA) PATIENTS IN A REAL-WORLD SETTING

    May 1, 2011, 00:00

  • PSS18 DISEASE SEVERITY EVALUATION AMONG DERMATOLOGICAL OUT-PATIENTS- A COMPARISON BETWEEN THE ASSESSMENTS OF PATIENTS AND PHYSICIANS

    May 1, 2011, 00:00

  • PIN44 REAL-WORLD EVALUATION OF THE ECONOMIC IMPACT OF DURATION OF DRUG THERAPY IN THE TREATMENT OF HEPATITIS C VIRUS (HCV)

    May 1, 2011, 00:00

  • PSY39 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN KAZAKHSTAN- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • PHP55 THE INFLUENCE OF COST-EFFECTIVENESS ISSUES OF THE APPRAISED ORPHAN DRUGS ON RECOMMENDATIONS OF AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AHTAPOL)

    May 1, 2011, 00:00

  • PCN5 USING HEALTH CLAIMS DATA TO STUDY PATTERNS OF CERVICAL CANCER SCREENING AND DIAGNOSIS IN A STATE MEDICAID FEE-FOR-SERVICE POPULATION (FUNDING- AHRQ – P20-HS15930)

    May 1, 2011, 00:00

  • PHP24 NUMBER AND TYPE OF DRUGS USED BY SENIORS ON PUBLIC DRUG PROGRAMS IN CANADA, 2002 TO 2008

    May 1, 2011, 00:00

  • PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS- A CANADIAN COST EFFECTIVENESS ANALYSIS

    May 1, 2011, 00:00

  • PSU1 FREQUENCIES, COSTS AND COMPLICATIONS OF CATHETER ABLATIONS FOR PEDIATRIC TACHYCARDIA- RESULTS FROM A NATIONAL PEDIATRIC INPATIENT DATABASE (YEARS 2000-2006)

    May 1, 2011, 00:00

  • PDB1 TREATMENT PATTERNS AND OUTCOMES AMONG OLDER EXENATIDE BID USERS COMPARED TO INSULIN GLARGINE USERS

    May 1, 2011, 00:00

  • PMD9 ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY AND LOSS OF QUALITY-ADJUSTED LIFE EXPECTANCY IN PATIENTS UNDER PROLONGED MECHANICAL VENTILATION- A POPULATION-BASED STUDY DURING 1998-2007 IN TAIWAN

    May 1, 2011, 00:00

  • PMD41 SELECTING A SECONDARY DATA SOURCE FOR A LOW-VOLUME PROCEDURE IN A SPECIALTY POPULATION- A STUDY USING INPATIENT PEDIATRIC COLONOSCOPY

    May 1, 2011, 00:00

  • PSY42 EPIDEMIOLOGY AND QALITY OF LIFE OF ANEMIC PATIENTS ON DIALYSIS IN RUSSIA- PATIENT-REPORTED DATA

    May 1, 2011, 00:00

  • PHP3 FEDERAL ENFORCEMENT ACTIONS AGAINST FRAUD AND ABUSE BY PHARMACEUTICAL MANUFACTURERS- 1996-2010

    May 1, 2011, 00:00

  • PRS36 HOSPITALIZATIONS, MEDICAL MANAGEMENT AND SWITCH THERAPY PATTERNS IN THE COPD MEDICARE POPULATION

    May 1, 2011, 00:00

  • PSY77 COMPARISON OF OBESITY-ASSOCIATED COMORBIDITIES BETWEEN EMR AND CLAIMS DATABASES

    May 1, 2011, 00:00

  • PHP91 ASSOCIATION BETWEEN QUALITY OF CARE AND SHORT TERM OUTCOMES FOR VERY OLD PATIENTS HOSPITALIZED FOR ACUTE ILLNESSES

    May 1, 2011, 00:00

  • PCV19 A BAYESIAN MULTIPLE TREATMENT COMPARISON OF PULMONARY ARTERIAL HYPERTENSION DRUG CLASSES BASED ON THE RISK OF MORTALITY REPORTED IN CLINICAL TRIALS

    May 1, 2011, 00:00

  • PMH58 NEW DISEASE MANAGEMENT PROGRAM FOR OPIOID DEPENDENT PATIENTS DECREASES DRUG USE AND INCREASES 12 STEP MEETING ATTENDANCE- ONE YEAR RESULTS OF A RANDOMIZED CLINICAL TRIAL

    May 1, 2011, 00:00

  • PRM36 NONPARAMETRIC ESTIMATION OF INCREMENTAL COST EFFECTIVENESS RATIO ACCOUNTING FOR SKEWNESS

    May 1, 2011, 00:00

  • PMD36 FAILURE OF INTERNATIONAL ORGANIZATION FOR STANDARDIZATION GUIDELINES TO REPORT CLINICALLY RELEVANT INFORMATION ABOUT POINT-OF-CARE INR DEVICE PERFORMANCE

    May 1, 2011, 00:00

  • PMD2 A META-ANALYSIS OF BIOMARKERS AND DIAGNOSTIC IMAGING IN ALZHEIMER'S DISEASE

    May 1, 2011, 00:00

  • PCN108 CLINICAL EFFICACY AND ONCOLOGY REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE INTERIM JOINT ONCOLOGY DRUG REVIEW (IJODR)

    May 1, 2011, 00:00

  • PIN14 ECONOMIC BURDEN OF SEVERE SEPSIS IN A VERTICALLY INTEGRATED HEALTH CARE SYSTEM (IHS)

    May 1, 2011, 00:00

  • PIH46 SPECIAL PRECAUTIONS TO CONSIDER WHEN PERFORMING COGNITIVE DEBRIEFING OF SENSITIVE TOPICS

    May 1, 2011, 00:00

  • PIH29 THE ROLE OF GENERATIONAL INFLUENCE TOWARDS COMPLEMENTARY AND ALTERNATIVE MEDICINE

    May 1, 2011, 00:00

  • PRM12 DOES DIFFERENTIAL DISCOUNTING ENHANCE DECISION MAKING?

    May 1, 2011, 00:00

  • PSY3 OPIOIDS IN NON-MALIGNANT PAIN- ARE THEY EQUIVALENT IN SAFETY PROFILE? A NETWORK META-ANALYSIS

    May 1, 2011, 00:00

  • PCV74 ASSESSMENT OF KNOWLEDGE ABOUT HYPERTENSION (HTN) AMONG HYPERTENSIVE PATIENTS IN SOUTHERN PUNJAB, PAKISTAN

    May 1, 2011, 00:00

  • PGI13 PERCEIVED VALUE ASSESSMENT OF ENTECAVIR VERSUS NO TREATMENT IN CHRONIC HEPATITIS B

    May 1, 2011, 00:00

  • PDB37 MAIL-ORDER PHARMACY USE AND MEDICATION ADHERENCE AMONG MEDICARE PART D BENEFICIARIES WITH DIABETES

    May 1, 2011, 00:00

  • PMH59 DIFFERENCES IN BASELINE PROBLEM SEVERITY BETWEEN PRESCRIPTION AND STREET OPIOID ABUSERS AMELIORATED AFTER PARTICIPATION IN DISEASE MANAGEMENT PROGRAM- RESULTS AT ONE YEAR

    May 1, 2011, 00:00

  • PRS30 COMPARISON OF CLINICAL AND PATIENT-REPORTED OUTCOME MEASURES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2011, 00:00

  • PCN133 ESTIMATING THE EPIDEMIOLOGY OF LATE-STAGE CANCERS – A MATHEMATICAL APPROACH

    May 1, 2011, 00:00

  • PCN90 PRO INSTRUMENTS USED TO MEASURE SYMPTOM IMPACTS OF FATIGUE AND PAIN IN PROSTATE CANCER DRUGS TRIALS

    May 1, 2011, 00:00

  • PCN105 ESTIMATING NICE'S COST EFFECTIVE THRESHOLD FOR END-OF-LIFE CANCER TREATMENTS

    May 1, 2011, 00:00

  • PSU17 EXCESS PAYMENTS FROM MEDICARE FOR INPATIENT SURGERY

    May 1, 2011, 00:00

  • PMH16 CHARACTERISTICS OF PATIENTS IN COMMUNITY BEHAVIORAL HEALTH ORGANIZATIONS RECEIVING TWO INJECTABLE FORMS OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS AS COMPARED WITH OTHER ANTIPSYCHOTICS

    May 1, 2011, 00:00

  • PCN61 COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER

    May 1, 2011, 00:00

  • PSU14 HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS ON KIDNEY TRANSPLANT WAITING LIST - WHAT FACTORS REALLY MATTER?

    May 1, 2011, 00:00

  • PDB49 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TYPE-2 DIABETES- KOREAN AUDIT OF DIABETES-DEPENDENT QUALITY-OF-LIFE

    May 1, 2011, 00:00

  • EV1 DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED OUTCOMES (PROS) IN POST-APPROVAL CLINICAL TRIALS OF ONCOLOGY DRUGS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)

    May 1, 2011, 00:00

  • PMH50 A TIME-TRADE-OFF STUDY OF HEALTH-RELATED QUALITY OF LIFE ADVANTAGE OF LONG-ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PIH5 RISK OF HIP AND SUBTROCHANTERIC OR DIAPHYSEAL FEMORAL FRACTURES IN ALENDRONATE USERS

    May 1, 2011, 00:00

  • PCN134 HUMANISTIC CONSEQUENCES OF PREVENTABLE BLADDER TUMOR RECURRENCES IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

    May 1, 2011, 00:00

  • PSY10 COST ANALYSIS OF ANEMIA TREATMENT WITH ERYTHROPOIESES-STIMULATING AGENTS (ESAS) IN CANCER PATIENTS RECEIVING CHEMOTHERAPY- A MULTICOUNTRY APPROACH

    May 1, 2011, 00:00

  • PCN60 COST-EFFECTIVENESS OF PEGFILGRASTIM VERSUS FILGRASTIM AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA AND MYELOMA

    May 1, 2011, 00:00

  • PCN64 ECONOMIC EVALUATION OF THREE FORMULATIONS OF LEUPROLIDE ACETATE IN ANDROGEN DEPRIVATION THERAPY FOR ADVANCED PROSTATE CANCER IN BELGIUM

    May 1, 2011, 00:00

  • PCN50 COST ANALYSIS OF DRG BASED FIRST LINE COLON CANCER THERAPIES IN HUNGARY

    May 1, 2011, 00:00

  • PCN39 COSTS AT THE END OF LIFE FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

    May 1, 2011, 00:00

  • PRS17 COST EFFECTIVENESS OF TOP 20 HIGHEST SELLING DRUGS

    May 1, 2011, 00:00

  • PDB34 PHARMACOECONOMIC EVALUATION OF A PHARMACIST-MANAGED DIABETES CLINIC

    May 1, 2011, 00:00

  • PRS21 RESOURCE USE AND COSTS OF EXACERBATION MANAGEMENT OF CHRONIC OBSTRUTIVE PULMONARY DISEASE PATIENTS UNDER THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL- ROLE OF MAINTENANCE TREATMENT IN THE EXACERBATION PREVENTION IN SEVERE PATIENTS

    May 1, 2011, 00:00

  • PCV95 USING COMPUTERIZED PHYSICIAN ORDER ENTRY OF ANTI-HYPERTENSIVE MEDICATIONS TO CONNECT INDICATIONS WITH PRESCRIBING AND IMPROVE PROBLEM LIST DOCUMENTATION

    May 1, 2011, 00:00

  • PCN47 ACUTE LYMPHOCYTIC LEUKEMIA-RELATED INPATIENT CARE AMONG PEDIATRIC PATIENTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN13 REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)- A PILOT STUDY IN FRANCE AND GERMANY ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY

    May 1, 2011, 00:00

  • PSY2 THE ASSOCIATION BETWEEN THERAPY WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND HEMOGLOBIN LEVEL

    May 1, 2011, 00:00

  • PCV65 NEW STATIN USERS' PERSISTENCE AND ADHERENCE- BOTH ARE CRITICAL CONCEPTS IN THE COMPREHENSIVE CHARACTERIZATION OF MEDICATION EXPOSURE

    May 1, 2011, 00:00

  • PHP103 COMPARATIVE EFFECTIVENESS REVIEWS AND THEIR POTENTIAL IMPACT ON FORMULARY ACCESS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PIH22 PRIMARY MEDICATION NONADHERENCE- A RETROSPECTIVE ANALYSIS OF ELECTRONIC PRESCRIPTIONS IN AN INTEGRATED HEALTHCARE SETTING

    May 1, 2011, 00:00

  • PCN69 AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF IMATINIB RESISTANT PATIENTS WITH ADVANCED PHASE CHRONIC MYELOGENOUS LEUKAEMIA

    May 1, 2011, 00:00

  • PHP101 VALUE BASED PRICING- WHAT IS THE FUTURE FOR PATIENT ACCESS SCHEMES?

    May 1, 2011, 00:00

  • PND29 VALIDATION OF THE HUNTINGTON CLINICAL SELF-REPORTED INSTRUMENT (H-CSRI), A CLINIMETRIC PATIENT ASSESSED SCALE FOR PATIENTS WITH HUNTINGTON'S DISEASE

    May 1, 2011, 00:00

  • PCN127 METHODS FOR INDIRECT COMPARISON OF EFFECTIVENESS IN COST-EFFECTIVENESS ANALYSES OF ONCOLOGY AGENTS- THE PROPORTIONAL HAZARDS ASSUMPTION MATTERS

    May 1, 2011, 00:00

  • PDB10 ASSESSING THE ABILITY OF PATIENT REPORTED MEASURES TO DISCRIMINATE PROXIES FOR TREATMENT RESPONSE

    May 1, 2011, 00:00

  • PCV2 THE RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIETARY CALCIUM AND VITAMIN D SUPPLEMENTS IN PATIENTS WITH OSTEOPOROSIS

    May 1, 2011, 00:00

  • PIN30 COST EFFECTIVENESS ANALYSIS OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAïVE ADULT PATIENTS WITH HIV INFECTION IN MEXICO

    May 1, 2011, 00:00

  • PRM16 VALIDATION AND PSYCHOMETRIC EVALUATION OF A 5-ITEM MEASURE OF PERCEIVED SOCIAL SUPPORT

    May 1, 2011, 00:00

  • PMS1 DO BISPHOSPHONATES CAUSE ATYPICAL FEMUR FRACTURES?

    May 1, 2011, 00:00

  • PMS28 COST-EFFECTIVNESS ANALYSIS OF NSAIDS FOR SYMTOMATIC TREATMENT OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS

    May 1, 2011, 00:00

  • PSY74 TREATMENT CHOICE FOR PAIN MANAGEMENT IN NURSING HOME HOSPICE/PALLIATIVE CARE RESIDENTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PDB30 A CROSS-SECTIONAL SURVEY ON ECONOMIC BURDEN OF TYPE-2 DIABETES MELLITUS PATIENTS WITH ORAL ANTI-DIABETIC DRUGS THERAPY IN CHINA

    May 1, 2011, 00:00

  • PHP26 ANALYSIS OF THE SIX PROTECTED MEDICATION CLASSES BASED ON PLAN TYPE AND LOW INCOME SUBSIDY STATUS

    May 1, 2011, 00:00

  • PMS73 PATIENT-CENTRIC OBSERVATIONAL STUDY ON CORRELATES OF INTENT TO PERSIST WITH TREATMENT- A REGRESSION MODEL IN OSTEOPOROSIS

    May 1, 2011, 00:00

  • PIN36 ANTIRETROVIRAL REFILL ADHERENCE IN COMMUNITY HIV SPECIALTY PHARMACIES (HIV-SP) VERSUS NON-SPECIALIZED PHARMACIES (NSP)

    May 1, 2011, 00:00

  • PRM43 BIOSIMILARS- DEMONSTRATING SIMILARITY THROUGH EVIDENCE

    May 1, 2011, 00:00

  • PIH24 RACIAL DISPARITIES IN MEDICATION UNDERUSE- THE ROLE OF PATIENT SATISFACTION WITH CARE

    May 1, 2011, 00:00

  • PMH46 THE EFFECT OF ANTIPSYCHOTIC ADHERENCE ON ADHERENCE TO DIABETES, HYPERLIPIDEMIA, AND HYPERTENSION MEDICATIONS AND ASSOCIATED HEALTH SERVICE UTILIZATION

    May 1, 2011, 00:00

  • PCN79 IMPACT OF NON-ADHERENCE TO IMATINIB ON PROGRESSION-FREE SURVIVAL AS 1ST TREATMENT FOR CHRONIC MYELOID LEUKEMIA IN BRAZIL- TWO YEARS FOLLOW UP

    May 1, 2011, 00:00

  • PCN118 PREDICTING THE FUTURE IMPACT OF EMERGING TECHNOLOGIES ON HEPATOCELLULAR CARCINOMA (HCC)- MEASURING STAKEHOLDERS PREFERENCES WITH BEST-WORST SCALING

    May 1, 2011, 00:00

  • PMS4 THE ASSOCIATION BETWEEN TERIPARATIDE PERSISTENCE AND FRACTURE OUTCOMES IN A US CLAIMS DATABASE

    May 1, 2011, 00:00

  • PRS27 THE DEVELOPMENT OF A PATIENT-REPORTED OUTCOME INSTRUMENT TO EVALUATE NIGHTTIME SYMPTOMS OF COPD

    May 1, 2011, 00:00

  • PGI19 HEALTH-RELATED QUALITY OF LIFE IS LOWER FOR PATIENTS WITH DIURNAL AND NOCTURNAL GERD SYMPTOMS

    May 1, 2011, 00:00

  • PHP4 WHEN STAKEHOLDERS DON'T AGREE- DISCREPANCIES IN MAB “APPROVALS” OVER THE PAST TEN YEARS

    May 1, 2011, 00:00

  • PMH54 CAREGIVER BURDEN IN SCHIZOPHRENIA - A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PHP10 THE TEMPORAL ASSOCIATION BETWEEN PRESCRIBED OPIOIDS AND THE NATIONAL DEATH RATE DUE TO OPIOID POISONING

    May 1, 2011, 00:00

  • PCN95 A SYSTEMATIC REVIEW OF QUALITY OF LIFE INSTRUMENTS IN LONG TERM BREAST CANCER SURVIVORS

    May 1, 2011, 00:00

  • PRS8 DISEASE PROGRESSION IN CYSTIC FIBROSIS — SYNTHESIS OF SURVIVAL EVIDENCE

    May 1, 2011, 00:00

  • PND3 THE NATURE AND PREVALENCE OF COMORBID ILLNESS AMONG INDIVIDUALS WITH MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PIH15 ECONOMIC EVALUATION OF ANALGESIC MANAGEMENT AFTER TOTAL ABDOMINAL HYSTERECTOMY AT THE SOCIAL SECURITY MEXICAN INSTITUTE

    May 1, 2011, 00:00

  • PSY21 COST-EFFECTIVENESS ANALISYS OF TREATMENT WITH AMFEPRAMONE (DIETHYLPROPION) IN OBESITY IN MEXICO

    May 1, 2011, 00:00

  • PSS11 COST-EFFECTIVENESS ANALYSIS OF FORMULARY MANAGEMENT STRATEGIES FOR FIRST-LINE AGENTS USED IN OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION

    May 1, 2011, 00:00

  • PSU7 A DISCRETE EVENT SIMULATION MODEL TO ESTIMATE THE LONG TERM OUTCOMES OF BARIATRIC SURGERY IN MEXICO

    May 1, 2011, 00:00

  • PMH55 THE BURDEN OF DIAGNOSED DEPRESSION AND SLEEP DIFFICULTIES ON QUALITY OF LIFE, WORK PRODUCTIVITY, AND RESOURCE USE

    May 1, 2011, 00:00

  • DS2 A VALIDATION STUDY OF ALGORITHMS FOR IDENTIFYING METASTATIC BREAST, LUNG, OR COLORECTAL CANCER IN ADMINISTRATIVE CLAIMS DATA

    May 1, 2011, 00:00

  • PHP32 ANALYSIS OF PHARMACISTS' INTERVENTIONS ON ELECTRONIC VERSUS TRADITIONAL PRESCRIPTIONS IN TWO COMMUNITY PHARMACIES

    May 1, 2011, 00:00

  • Guide for Authors

    May 1, 2011, 00:00

  • PHP28 COMPLIANCE WITH TREATMENT GUIDELINE RECOMMENDATIONS- USE OF OVER-THE-COUNTER MEDICATIONS IN PATIENTS RECEIVING BISPHOSPHONATES, ANTIEPILEPTICS, OR CHRONIC OPIOIDS

    May 1, 2011, 00:00

  • PIH40 RETROSPECTIVE DATABASE ANALYSIS OF TREATMENT PATTERNS AND HEALTH CARE COSTS AMONG WOMEN WITH IDIOPATHIC HEAVY MENSTRUAL BLEEDING

    May 1, 2011, 00:00

  • PRM35 DEVELOPMENT OF A CONCEPT LIST TO ENSURE COMPARABLE CONTENT VALIDITY BETWEEN ORIGINAL PRO QUESTIONNAIRES AND THEIR TRANSLATIONS- A REVIEW OF 15 YEARS OF LINGUISTIC VALIDATIONS

    May 1, 2011, 00:00

  • PND38 THE HIDDEN TOLL OF CAREGIVER BURDEN IN MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PDB21 A COST COMPARISON OF A BASAL BOLUS REGIMEN (INSULIN GLARGINE AND INSULIN GLULISINE) WITH A CONVENTIONAL PRE-MIXED INSULIN REGIMEN IN TYPE-2 DIABETES PATIENTS – THE GINGER STUDY

    May 1, 2011, 00:00

  • PMH63 RISK-BENEFIT ANALYSIS OF DEPRESSION TREATMENT FOR CHILDREN AND YOUNG ADULTS

    May 1, 2011, 00:00

  • PRM49 TRANSLATION AND LINGUISTIC VALIDATION – METHODOLOGICAL IMPLICATIONS WHEN THE SOURCE MEASURE IS NOT ENGLISH

    May 1, 2011, 00:00

  • PMH32 COMPARISON OF REAL-WORLD HEALTH CARE COSTS AFTER THE INITIATION OF SECOND-LINE DULOXETINE OR GENERIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH MAJOR DEPRESSIIVE DISORDER

    May 1, 2011, 00:00

  • PMS53 USE OF TNF-INHIBITORS IN THE UNITED STATES- UTILIZATION PATTERNS AND DOSE-ESCALATION FROM A REPRESENTATIVE UNITED STATES RA POPULATION

    May 1, 2011, 00:00

  • PDB39 A DESCRIPTIVE ANALYSIS OF TREATMENT ADHERENCE WITH GROWTH HORMONE- FINDINGS FROM A NATIONAL MANAGED CARE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PUK4 CUMULATIVE EXPOSURE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AND THE PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD)

    May 1, 2011, 00:00

  • PCV104 REAL-WORLD SIDE EFFECT DATA ON CHOLESTEROL MEDICATIONS – OUTPUTS FROM AN ONLINE PATIENT COMMUNITY

    May 1, 2011, 00:00

  • PMH52 PATIENT AND PHYSICIAN PREFERENCES AND SATISFACTION WITH ORAL AND LONG-ACTING INJECTABLE LONG-TERM ANTIPSYCHOTIC TREATMENT FOR PSHYCHOTIC DISORDERS

    May 1, 2011, 00:00

  • EE1 SYSTEMATIC REVIEW OF GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS

    May 1, 2011, 00:00

  • PSY27 REAL-WORLD EVALUATION OF HEALTH CARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (PDPN) TREATED WITH PREGABALIN OR GABAPENTIN

    May 1, 2011, 00:00

  • PDB23 THE IMPACT OF TREATMENT MODIFICATION ON HEALTHCARE EXPENDITURE IN PATIENTS WITH TYPE-2 DIABETES INITIATING EXENATIDE BID OR INSULIN GLARGINE

    May 1, 2011, 00:00

  • PHP13 THE IMPACT OF A QUALITY IMPROVEMENT INITIATIVE ON INAPPROPRIATE MEDICATION USE IN THE OUTPATIENT ELDERLY

    May 1, 2011, 00:00

  • PRS20 A COST-UTILITY ANALYSIS ON THE USE OF INDACATEROL FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN MEXICO

    May 1, 2011, 00:00

  • PCV98 USE OF ELECTRONIC MEDICAL RECORDS TO ASSESS THE CLINICAL AND ECONOMIC IMPACT OF NON-MEDICAL SWITCHING BETWEEN DIFFERENT ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)

    May 1, 2011, 00:00

  • PMD25 THE COST-UTILITY AND VALUE OF INFORMATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION COMPARED TO STANDARD MANAGEMENT AND SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC VALVE STENOSIS

    May 1, 2011, 00:00

  • PRM15 ADHERENCE IS ADHERENCE IS ADHERENCE- THE CONSISTENCY OF MORISKY ADHERENCE SCORES ACROSS THE COSTLIEST CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • PND44 HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS WITH DYSPORT IN CERVICAL DYSTONIA

    May 1, 2011, 00:00

  • PCV91 BETA BLOCKERS AND DIURETICS USAGE IN CROATIA AND SLOVENIA DURING A NINE-YEAR PERIOD

    May 1, 2011, 00:00

  • PHP107 BIOMARKERS- A CHANGING PARADIGM FOR DEVELOPMENT

    May 1, 2011, 00:00

  • PDB46 DEVELOPMENT OF THE DIABETIC PERIPHERAL NEUROPATHIC PAIN IMPACT MEASURE- A PATIENT-REPORTED OUTCOME MEASURE OF THE IMPACT OF DPNP ON FUNCTIONING

    May 1, 2011, 00:00

  • PMD5 OUTCOME STUDY OF DRUG ELUTING STENT (DES) VERSUS BARE METAL STENT (BMS) IN HONG KONG- A 6-MONTH PILOT STUDY

    May 1, 2011, 00:00

  • PHP25 THE POTENTIAL VALUE OF THE 2014 MEDICAID EXPANSION

    May 1, 2011, 00:00

  • PSS8 SYSTEMATIC REVIEW OF THE ECONOMIC LITERATURE ON ATOPIC DERMATITIS IN CHILDREN

    May 1, 2011, 00:00

  • PMH14 CLINICAL EFFECTIVENESS ANALYSIS OF NALTREXONE VERSUS ACAMPROSATE AND PLACEBO IN ALCOHOL DEPENDENT PATIENTS TREATED WITH PSYCHOTHERAPY

    May 1, 2011, 00:00

  • PCN121 ONCOLOGY MEDICATION UTILIZATION BASED ON FEDERAL DRUG ADMINISTRATION (FDA) LABELING, NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINE (GL) RECOMMENDATIONS, AND EVIDENCE FOR PATIENTS WITH ADVANCED NON SMALL CEL ...

    May 1, 2011, 00:00

  • PCN22 ASSESSMENT OF SAFETY PROFILE OF TRASTUZUMAB IN METASTATIC BREAST CANCER PATIENTS

    May 1, 2011, 00:00

  • PGI1 INCIDENCE OF ANEMIA AND NEUTROPENIA FOLLOWING HCV TREATMENT INITIATION AND RELATED DRUG TREATMENT COSTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS18 IMPACT OF TREATMENT PERSISTENCE AND COMPLIANCE ON HEALTH CARE RESOURCE UTILISATION AND TOTAL HEALTH CARE COST IN POST MENOPAUSAL WOMEN PRESCRIBED ORAL BISPHOSPHONATES – A RETROSPECTIVE STUDY USING THE GENERAL PRACTICE RESEARCH DATABAS ...

    May 1, 2011, 00:00

  • PIH2 LEAD DETOXIFYING EFFECT OF VITAMIN C IN TRAFFIC POLICE SUBJECTS

    May 1, 2011, 00:00

  • PCV54 EFFECTIVENESS OF DISEASE MANAGEMENT CARE IN THE CASE OF HEART FAILURE

    May 1, 2011, 00:00

  • PMS35 COST UTILITY ANALISYS OF CHONDROITIN SULPHATE(CS) IN THE TREATMENT OF OSTEOARTHRITIS (OA) OF THE KNEE IN MEXICAN PATIENTS

    May 1, 2011, 00:00

  • PMH13 COMPARATIVE EFFECTIVENESS STUDY OF RISPERIDONE LONG-ACTING INJECTABLE- THE USE OF DYNAMIC EXPOSURE METHODOLOGY FOR RISK SHARING AGREEMENT

    May 1, 2011, 00:00

  • PIN45 IMPACT OF GOVERNMENT SPONSORED POLIO CONTROL PROGRAM ON KNOWLEDGE, ATTITUDE AND PERCEPTION OF POLIO IN GENERAL COMMUNITY OF BAHAWALPUR, PAKISTAN

    May 1, 2011, 00:00

  • PUK21 PATIENT CHARACTERISTICS ASSOCIATED WITH INITIATION OF OVERACTIVE BLADDER (OAB) DISCUSSION WITH A PHYSICIAN

    May 1, 2011, 00:00

  • PDB48 DO WE KNOW WHAT ARE THEY TRADING OFF? – A FEASIBILITY STUDY TO MEASURE QUALITY OF LIFE IN TAIWANESE TYPE-2 DIABETES OUTPATIENTS BY TIME-TRADE-OFF METHOD

    May 1, 2011, 00:00

  • PCV75 EFFECT OF ACEI AND ARB ON HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERTENSION AND DIABETES

    May 1, 2011, 00:00

  • PCN32 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA OUTPATIENTS

    May 1, 2011, 00:00

  • PSS6 SAFETY PROFILE OF LATANOPROST VERSUS TIMOLOL IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION- POST 2000 SETTING

    May 1, 2011, 00:00

  • PCV86 INSURANCE STATUS AND THE USE OF ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) AND ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS AMONG POST-MYOCARDIAL INFARCTION (MI) PATIENTS

    May 1, 2011, 00:00

  • PMS5 PERSISTENCE WITH BISPHOSPHONATE THERAPY AND RISK OF HIP FRACTURE

    May 1, 2011, 00:00

  • PHP15 ISSUES ASSOCIATED WITH BIOLOGIC AGENTS- HEALTHCARE STAKEHOLDER SURVEY

    May 1, 2011, 00:00

  • PGI17 HCV TREATMENT CONTINUATION RATES IN GENOTYPE 1 PATIENTS IN A REAL-WORLD SETTING IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN8 REAL LIFE OUTCOMES IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)- A PILOT STUDY IN FRANCE AND GERMANY ANALYSING BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB-BASED TREATMENTS

    May 1, 2011, 00:00

  • PRS32 HOSPITAL COST VERSUS MEDICARE PAYMENT FOR RESPIRATORY INSUFFICIENCY, ARREST AND FAILURE

    May 1, 2011, 00:00

  • PMS57 ASSOCIATION OF CLINICAL REMISSION AND NORMALIZED PATIENT REPORTED OUTCOMES- A VALIDATION OF TREAT-TO-TARGET FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING POOLED DATA FROM 3 PHASE III GOLIMUMAB CLINICAL TRIALS

    May 1, 2011, 00:00

  • PCN54 INJECTION OF LONG-ACTING SOMATOSTATIN ANALOGS- A COST CONSEQUENCE ANALYSIS IN FRANCE, GERMANY, THE UNITED KINGDOM AND THE UNITED STATES

    May 1, 2011, 00:00

  • DU3 IMPACT OF THE FDA'S ANTIPSYCHOTIC BLACK BOX WARNING ON PSYCHOTROPIC DRUG PRESCRIBING IN ELDERLY PATIENTS WITH DEMENTIA IN OUTPATIENT AND OFFICE-BASED SETTINGS

    May 1, 2011, 00:00

  • IN2 ASSOCIATION BETWEEN DRUG TOLERABILITY AND ECONOMIC IMPACT FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT

    May 1, 2011, 00:00

  • PCN31 DIRECT MEDICAL COSTS OF ELDERLY PATIENTS WITH STAGE III COLON CANCER DURING FIRST-LINE VERSUS SECOND-LINE CHEMOTHERAPY

    May 1, 2011, 00:00

  • PRS23 NON-ADHERENCE IN ISONIAZID TREATED PATIENTS AS MEASURED BY THE TEMPTATION TO SKIP THERAPY (TEST) SCALE

    May 1, 2011, 00:00

  • PMD1 IMPACT OF VAGUS NERVE STIMULATION (VNS) THERAPY ON CLINICAL OUTCOMES AND COSTS IN MEDICAID PATIENTS WITH DRUG-RESISTANT EPILEPSY

    May 1, 2011, 00:00

  • PIN10 ECOMOMIC EVALUATION OF DAPTOMYCIN COMPARE WITH STANDARD THERAPY IN THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA WITH OR WITHOUT ENDOCARDITIS IN COLOMBIA

    May 1, 2011, 00:00

  • PHP95 EXPECTED CHANGES IN HEALTH CARE UTILIZATION DUE TO PATIENT PROTECTION AND AFFORDABLE CARE ACT

    May 1, 2011, 00:00

  • PCN126 OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC)- THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

    May 1, 2011, 00:00

  • PDB59 THE COMPLEXITY OF DRUG THERAPY AND SOCIO-ECONOMIC VARIANTS IN PATIENTS WITH DIABETES

    May 1, 2011, 00:00

  • PND52 HEALTH CARE RESOURCE UTILIZATION BEFORE AND AFTER INITIATION OF ARMODAFINIL TREATMENT FOR WAKEFULNESS

    May 1, 2011, 00:00

  • PGI15 COST EFFECTIVENES OF THE PHARMACOLOGIC TREATMENT OF IRRITABLE BOWEL SYNDROME AT THE SOCIAL SECURITY MEXICAN INSTITUTE

    May 1, 2011, 00:00

  • PND16 CHARACTERIZING DIRECT COSTS ASSOCIATED WITH HEMOPHILIA A- A RESOURCE-BASED COST ANALYSIS

    May 1, 2011, 00:00

  • PSY1 SEVERE RENAL, HEPATIC AND GASTROINTESTINAL EVENTS ASSOCIATED WITH DEFERASIROX IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA

    May 1, 2011, 00:00

  • PHP8 PHYSICIAN SHORTAGE IMPACT ON PATIENT RX USE FOR SELECT CHRONIC CONDITIONS

    May 1, 2011, 00:00

  • PMH39 COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPIES IN KOREA

    May 1, 2011, 00:00

  • PSY80 PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY

    May 1, 2011, 00:00

  • PSY20 ECONOMIC EVALUATION OF SEQUENTIAL ANALGESIC TREATMENT IN THE MANAGEMENT OF MODERATE ANKLE SPRAIN IN MEXICAN ADULTS

    May 1, 2011, 00:00

  • PCN96 CANCER PATIENT PREFERENCES AND WILLINGNESS TO PAY FOR PREVENTING CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN THE UNITED STATES

    May 1, 2011, 00:00

  • PRM14 VALIDATING AN ONLINE CALCULATOR FOR EVALUATING HEALTH INTERVENTION OPTIONS USING THE ANALYTIC HIERARCHY PROCESS (AHP)

    May 1, 2011, 00:00

  • PRS22 COPD MAINTENANCE MEDICATION ADHERENCE- INFLUENCE ON HOSPITALIZATION AND SPENDING IN A MEDICARE POPULATION

    May 1, 2011, 00:00

  • PMD11 IDENTIFYING POTENTIAL DRIVERS OF COST SAVINGS WITH INSULIN ADMINISTRATION DEVICES IN TYPE-2 DIABETES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS38 IMPACT OF MEDICARE PART D COVERAGE GAP ON MEDICATION TAKING BEHAVIOR- AN EVALUATION ACROSS DUAL AND NON-DUAL ELIGIBLE BENEFICIARIES DIAGNOSED WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PCN136 ESTIMATING UTILITIES IN CANCER- A COMPARISON OF EQ-5D AND FACT-BASED ALGORITHMS

    May 1, 2011, 00:00

  • PRS18 THE COST-EFFECTIVENESS OF ROFLUMILAST IN THE MANAGEMENT OF SEVERE COPD IN THE UK SETTING

    May 1, 2011, 00:00

  • PDB56 IMPACT OF PHARMACIST MANAGEMENT ON PATIENTS WITH DIABETES ENROLLED IN A RURAL FREE CLINIC

    May 1, 2011, 00:00

  • PGI22 CONCORDANCE AMONG MULTIPLE HEALTH OUTCOMES MEASURES IN RESPONSIVENESS TO MULTI-MATRIX MESALAMINE MAINTENANCE TREATMENT FOR PATIENTS WITH QUIESCENT ULCERATIVE COLITIS

    May 1, 2011, 00:00

  • PMH78 PERSISTENCE OF STIMULANT TREATMENT IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PGI21 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS BEFORE AND AFTER 8 WEEKS' TREATMENT WITH MULTI-MATRIX MESALAMINE- COMPARISON WITH 2009 GENERAL POPULATION NORMS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCV34 PROPHYLAXIS USE AND 90-DAY COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENT ANALYSIS IN HOSPITALIZED MEDICALLY ILL PATIENTS

    May 1, 2011, 00:00

  • PCV84 EFFECTIVENESS OF A MEDICAL EDUCATION INTERVENTION TO TREAT HYPERTENSION IN PRIMARY CARE

    May 1, 2011, 00:00

  • PCN43 STUDY ON MEDICAL EXPENDITURE AND PAYMENT PATTERNS OF INSURED PATIENTS WITH CANCER IN CHINA

    May 1, 2011, 00:00

  • PCN28 COST SAVINGS WITH FERRIC CARBOXYMALTOSE THROUGH ITS IMPACT ON ERYTHROPOÏESIS-STIMULATING AGENTS AND BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED ANEMIA OF BREAST AND GASTROINTESTINAL CANCER- FRENCH HEALTH CARE PAYER PERSPECTIVE

    May 1, 2011, 00:00

  • PCV22 META REGRESSION ANALYSIS TO INDIRECTLY COMPARE THE SAFETY AND EFFICACY OF DALTEPARIN TO ENOXAPARIN IN PATIENTS WITH UNSTABLE CORONARY ARTERY DISEASE

    May 1, 2011, 00:00

  • PND61 EVALUATION OF CONSISTENCY BETWEEN MULTIPLE SCLEROSIS REGISTRY PUBLICATIONS

    May 1, 2011, 00:00

  • PMS67 FREQUENCY OF SELECT ANTI-TNF ADMINISTRATION OR RE-FILL IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PND35 CREATION OF A WEB-BASED MULTIPLE SCLEROSIS PATIENT-REPORTED OUTCOMES RESEARCH PROGRAM

    May 1, 2011, 00:00

  • PDB64 EVALUATION OF THE BURDEN OF ILLNESS OF TYPE-2 DIABETES MELLITUS IN A MEDICARE POPULATION

    May 1, 2011, 00:00

  • PCN62 BAYESIAN MODELLING ASSESSING THE EFFECTIVENESS OF A VACCINATION STRATEGY TO PREVENT HPV-RELATED DISEASES- THE BEST STUDY

    May 1, 2011, 00:00

  • PSY26 IMPACT OF HYPONATREMIA ON PATIENT OUTCOMES AND HEALTH CARE RESOURCE UTILIZATION IN HOSPITALIZED PATIENTS

    May 1, 2011, 00:00

  • PCN97 IMPACT OF GLOBAL HEALTH CARE REFORMS ON PRICING, ACCESS AND HEALTH ECONOMICS AND OUTCOMES STRATEGY

    May 1, 2011, 00:00

  • SB4 A METHODOLOGY FOR ASSESSING TREATMENT EFFECT IN THE PRESENCE OF DISEASE SEVERITY AND COMORBIDITY IN RETROSPECTIVE OBSERVATIONAL STUDIES

    May 1, 2011, 00:00

  • PHP60 ORPHAN DRUGS FACE TOUGHER SCRUTINY IN SECURING FAVORABLE PRICING AND MARKET ACCESS

    May 1, 2011, 00:00

  • PSS9 COST-EFFECTIVENESS OF COLLAGENASE VERSUS HYDROGEL DRESSINGS FOR CHRONIC-WOUND DEBRIDEMENT IN A LONG-TERM CARE SETTING

    May 1, 2011, 00:00

  • PCV8 EVALUATION OF A SAFETY INITIATIVE AND OUTCOMES FOR PATIENTS ON STATIN-FIBRATE COMBINATION THERAPIES IN THE VETERANS AFFAIRS POPULATION

    May 1, 2011, 00:00

  • PRS11 ESTIMATING THE ECONOMIC BURDEN OF FOOD-INDUCED ALLERGIC REACTIONS AND ANAPHYLAXIS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSY12 BASELINE CHARACTERISTICS AND PRE–INDEX TOTAL HEALTH CARE AND RHEUMATOID ARTHRITIS-RELATED COSTS IN PATIENTS RECEIVING GOLIMUMAB THERAPY

    May 1, 2011, 00:00

  • PIN23 COST-EFFECTIVENESS OF ATAZANAVIR/RITONAVIR (ATV+RTV) COMPARED WITH LOPINAVIR/RITONAVIR (LPV+RTV) IN TREATMENT-NAÏVE HIV-INFECTED PATIENTS IN MEXICO- A MODEL BASED ON THE CASTLE STUDY

    May 1, 2011, 00:00

  • CE4 USING DYNAMIC TRANSMISSION MODELS TO ESTIMATE THE COST EFFECTIVENESS OF VACCINES- FOUR DIFFERENT METHODS AND THEIR RELEVANCE FOR DECISION MAKERS

    May 1, 2011, 00:00

  • PCN84 PATIENTS' PREFERENCES FOR THE TREATMENT OF COLORECTAL CANCER- A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY

    May 1, 2011, 00:00

  • PHP75 USE OF ELECTRONIC MEDICAL RECORDS FROM 2001 THROUGH 2010- IMPLICATIONS FOR COMPARATIVE EFFECTIVENESS RESEARCH

    May 1, 2011, 00:00

  • PHP78 CHARACTERISTICS OF HOMELESS INDIVIDUALS USING INPATIENT AND EMERGENCY DEPARTMENT SERVICES

    May 1, 2011, 00:00

  • PMS12 DIRECT AND INDIRECT COSTS ASSOCIATED WITH DUPUYTREN'S CONTRACTURE

    May 1, 2011, 00:00

  • PND45 ONE YEAR OF NATALIZUMAB TREATMENT IS ASSOCIATED WITH AN IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS

    May 1, 2011, 00:00

  • PIH3 COMPARISON OF IN VITRO FERTILIZATION TRENDS AMONG INSURED PATIENTS IN MANAGED CARE IN THE UNITED STATES; COMPARISON OF STATES WITH AND WITHOUT MANDATED COMPREHENSIVE FERTILITY COVERAGE

    May 1, 2011, 00:00

  • PCV66 ADHERENCE RATES AMONG HEALTH PLAN MEMBERS STARTING GENERIC VERSUS BRAND STATIN THERAPY

    May 1, 2011, 00:00

  • PSY35 VALIDATION OF THE LUPUS IMPACT TRACKER

    May 1, 2011, 00:00

  • PMH68 FDA REGULATIONS AND ANTIDEPRESSANT UTILIZATION

    May 1, 2011, 00:00

  • PDB58 WHAT IS THE IMPACT OF GENERIC SUBSTITUTION OF ROSIGLITAZONE ON PATIENT OUTCOMES AND TREATMENT COSTS? AN HMO EXPERIENCE

    May 1, 2011, 00:00

  • PCN120 WHO CHOSE PRIMARY ANDROGEN DEPRIVATION THERAPY OVER RADICAL PROSTATECTOMY- A RETROSPECTIVE STUDY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER

    May 1, 2011, 00:00

  • PRM6 DEVELOPMENT OF AN INCREMENTAL COST-EFFECTIVENESS RATIO WITH SOME EQUITY IMPLICATION

    May 1, 2011, 00:00

  • PMH22 CLINICAL AND ECONOMIC CONSEQUENCES OF LONG-TERM USE OF BENZODIAZEPINES IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

    May 1, 2011, 00:00

  • PCV7 ANALYSIS OF TREATMENT PATTERNS AND COSTS FOR VENOUS THROMBOEMBOLISM, MAJOR AND MINOR BLEEDING EVENTS IN HOSPITALIZED MEDICALLY ILL PATIENTS

    May 1, 2011, 00:00

  • PCN130 RECORD-LINKAGE FOR PHARMACOEPIDEMIOLOGIC STUDIES IN CANCER PATIENTS

    May 1, 2011, 00:00

  • PSY78 ESTIMATING THE BMI-MORTALITY RELATION USING FRACTIONAL POLYNOMIALS

    May 1, 2011, 00:00

  • PSY51 EFFECTIVENESS OF FDA'S NEW OVER-THE-COUNTER ACETAMINOPHEN LABEL WARNING REQUIREMENTS IN IMPROVING CONSUMER RISK PERCEPTION OF LIVER DAMAGE

    May 1, 2011, 00:00

  • PMS34 COST-UTILITY ANALYSIS OF DENOSUMAB VERSUS RALOXIFENE FOR TREATING OSTEOPOROSIS IN POST-MENOPAUSAL WOMEN IN THE UNITED STATES

    May 1, 2011, 00:00

  • PRS15 ECONOMIC EVALUATION OF FLUTICASONE FUROATE COMPARED WITH MOMETASONA FUROATE FOR THE PRIMARY TREATMENT OF ALLERGIC RHINITIS PATIENTS

    May 1, 2011, 00:00

  • PSS3 PERSISTENCE WITH STATINS AND THE RISK OF AGE RELATED MACULAR DEGENERATION IN A LARGE HEALTH ORGANIZATION IN ISRAEL

    May 1, 2011, 00:00

  • PCN19 AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASES IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • QA2 CROSS-WALKING CANCER-SPECIFIC INSTRUMENTS TO THE EQ-5D AND SF-6D

    May 1, 2011, 00:00

  • PSU18 IMPACT OF HEALTH INSURANCE ON RECEIVING BREAST CONSERVING SURGERY WITH RADIATION IN FLORIDA

    May 1, 2011, 00:00

  • PMS42 CONTENT VALIDITY AND HEALTH CARE SYSTEMS- A CASE-STUDY

    May 1, 2011, 00:00

  • PHP111 OVER INFLATION OF THE GENETIC CONTRIBUTION TO SCHIZOPHRENIA- IMPLICATIONS FOR NOVEL THERAPEUTICS

    May 1, 2011, 00:00

  • PGI5 COMPARISON OF HEALTH CARE UTILIZATIONS BETWEEN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE WHO SWITCHED FROM A BRANDED PROTON PUMP INHIBITOR TO A GENERIC PROTON PUMP INHIBITOR AND VICE VERSA

    May 1, 2011, 00:00

  • PCN16 MAJOR CHANGES IN CHEMOTHERAPY REGIMENS ADMINISTERED TO BREAST CANCER PATIENTS DURING 2000-2008

    May 1, 2011, 00:00

  • PGI6 THE ECONOMIC BURDEN OF ADVANCED LIVER DISEASE AMONG PATIENTS WITH HEPATITIS C VIRUS- A STATE MEDICAID PERSPECTIVE

    May 1, 2011, 00:00
  • «
  • 131 (current)
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • »